AU2007240120A1 - Method of treatment of age-related macular degeneration (AMD) - Google Patents

Method of treatment of age-related macular degeneration (AMD) Download PDF

Info

Publication number
AU2007240120A1
AU2007240120A1 AU2007240120A AU2007240120A AU2007240120A1 AU 2007240120 A1 AU2007240120 A1 AU 2007240120A1 AU 2007240120 A AU2007240120 A AU 2007240120A AU 2007240120 A AU2007240120 A AU 2007240120A AU 2007240120 A1 AU2007240120 A1 AU 2007240120A1
Authority
AU
Australia
Prior art keywords
optionally substituted
cells
pct
neuronal
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007240120A
Other languages
English (en)
Other versions
AU2007240120A2 (en
Inventor
Mariana El Sous
Penelope Jane Huggins
Vijaya Kenche
Gaik Beng Kok
Jack Gordon Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Publication of AU2007240120A1 publication Critical patent/AU2007240120A1/en
Publication of AU2007240120A2 publication Critical patent/AU2007240120A2/en
Priority to AU2010206074A priority Critical patent/AU2010206074B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007240120A 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration (AMD) Abandoned AU2007240120A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010206074A AU2010206074B2 (en) 2006-04-14 2010-07-30 Method of treatment of age-related macular degeneration (AMD)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14
US60/792,278 2006-04-14
PCT/AU2007/000490 WO2007118276A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010206074A Division AU2010206074B2 (en) 2006-04-14 2010-07-30 Method of treatment of age-related macular degeneration (AMD)

Publications (2)

Publication Number Publication Date
AU2007240120A1 true AU2007240120A1 (en) 2007-10-25
AU2007240120A2 AU2007240120A2 (en) 2008-12-18

Family

ID=38608967

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2007240120A Abandoned AU2007240120A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration (AMD)
AU2010206074A Ceased AU2010206074B2 (en) 2006-04-14 2010-07-30 Method of treatment of age-related macular degeneration (AMD)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010206074A Ceased AU2010206074B2 (en) 2006-04-14 2010-07-30 Method of treatment of age-related macular degeneration (AMD)

Country Status (14)

Country Link
US (3) US20100144693A1 (enExample)
EP (2) EP2012789B1 (enExample)
JP (1) JP5290147B2 (enExample)
KR (2) KR20100110396A (enExample)
CN (3) CN102225930A (enExample)
AU (2) AU2007240120A1 (enExample)
BR (2) BRPI0710737A2 (enExample)
CA (1) CA2683756A1 (enExample)
DK (1) DK2012789T3 (enExample)
ES (1) ES2437997T3 (enExample)
IL (1) IL207495A (enExample)
NZ (2) NZ572591A (enExample)
WO (1) WO2007118276A1 (enExample)
ZA (2) ZA200809493B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007262670B2 (en) * 2006-06-22 2012-12-20 Prana Biotechnology Limited Method of treatment of glioma brain tumour

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
CN102177152A (zh) * 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
ES2634492T3 (es) * 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona
UA103366C2 (ru) 2009-01-26 2013-10-10 Майкл Спіно Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
JP2016503797A (ja) 2012-12-20 2016-02-08 アルデイラ セラピューティクス， インコーポレイテッド ペリ−カルビノール
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CA2898869A1 (en) 2013-01-25 2014-07-31 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
CN111961050A (zh) 2014-12-02 2020-11-20 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
CN107533181B (zh) * 2015-04-29 2020-06-30 特里亚佩克斯有限公司 偏光膜、制备它的方法及包含它的偏光镜片
US10781178B2 (en) * 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
WO2017053696A2 (en) * 2015-09-24 2017-03-30 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
WO2017196881A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2017288056A1 (en) 2016-07-01 2019-01-17 Prana Biotechnology Limited Method of treating immunoglobulin light chain amyloidosis
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CN109232396B (zh) * 2018-11-27 2020-07-03 聊城大学 酰胺吡啶类衍生物及其用途
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
EP4175636A2 (en) * 2020-07-02 2023-05-10 The United States of America, as represented by the Secretary, Department of Health and Human Services Cyclic compounds for use in treating retinal degeneration
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (enExample) 1950-09-09
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
CA2160119A1 (en) 1993-04-08 1994-10-27 David Jay Meisner Sanitary water tap
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
TR199900293T2 (xx) 1996-08-13 1999-06-21 P.N. Gerolymatos S.A. Alzheimer hastal��� tedavisi i�in bir farmas�tik bile�im �retmek �zere �elat maddesi clioquil'un kullan�m�.
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
PL198852B1 (pl) 1998-10-22 2008-07-31 Neurosearch As Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
WO2001016114A2 (en) 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
FR2819187A1 (fr) * 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
EP1427726A1 (en) 2001-08-17 2004-06-16 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
NZ539211A (en) * 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
CN1791408A (zh) * 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
CA2529257C (en) * 2003-06-23 2013-04-23 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
JP4937111B2 (ja) * 2004-04-02 2012-05-23 プラナ バイオテクノロジー リミティッド 神経学的に活性な化合物
US20110020237A1 (en) * 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
DK2044026T3 (da) * 2006-06-22 2014-06-30 Prana Biotechnology Ltd Fremgangsmde til behandling af cerebral glioma tumor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007262670B2 (en) * 2006-06-22 2012-12-20 Prana Biotechnology Limited Method of treatment of glioma brain tumour

Also Published As

Publication number Publication date
US20100144693A1 (en) 2010-06-10
AU2007240120A2 (en) 2008-12-18
BRPI0722382A2 (pt) 2012-06-05
IL207495A (en) 2015-05-31
DK2012789T3 (da) 2013-12-16
NZ572591A (en) 2012-01-12
AU2010206074B2 (en) 2012-08-30
CN101987849A (zh) 2011-03-23
CN102225930A (zh) 2011-10-26
AU2010206074A1 (en) 2010-08-19
JP2009533356A (ja) 2009-09-17
JP5290147B2 (ja) 2013-09-18
ZA200809493B (en) 2010-08-25
IL207495A0 (en) 2010-12-30
CN101987849B (zh) 2013-05-08
EP2012789B1 (en) 2013-09-25
BRPI0710737A2 (pt) 2011-05-10
EP2012789A4 (en) 2011-02-16
EP2514423A3 (en) 2012-12-19
WO2007118276A1 (en) 2007-10-25
KR20080109096A (ko) 2008-12-16
US20110071167A1 (en) 2011-03-24
NZ590271A (en) 2011-12-22
US9163018B2 (en) 2015-10-20
CA2683756A1 (en) 2007-10-25
CN101534826A (zh) 2009-09-16
KR20100110396A (ko) 2010-10-12
EP2514423A2 (en) 2012-10-24
EP2012789A1 (en) 2009-01-14
ES2437997T3 (es) 2014-01-15
ZA201005922B (en) 2013-09-25
US20140088122A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
AU2007240120A1 (en) Method of treatment of age-related macular degeneration (AMD)
KR101122782B1 (ko) 신경 활성 화합물
KR101149323B1 (ko) 8-하이드록시 퀴놀린 유도체
DK2379510T3 (en) quinazolinone
AU2019208176A1 (en) Antibacterial therapeutics and prophylactics
KR101892885B1 (ko) 의약으로서 3,6-이중치환된 크산틸륨 염
JP2022511374A (ja) Ｖａｐ－１の阻害剤
AU2009215107B2 (en) Treatments for neuropathy
KR20090023621A (ko) 9-하이드록시 엘립티신 유도체를 이용한 악성 표현형의 복구
CA2711638C (en) 3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases
KR20100051837A (ko) 소아 종양의 치료
JPH05140158A (ja) 緑内障の治療に有用な置換ピリジン誘導体
AU2003265740B2 (en) Neurologically-active compounds
US20140228392A1 (en) Compositions and methods for treating cancer
AU2013203934A1 (en) Treatments for neuropathy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE CO-INVENTOR BUSH, ASHLEY; MASTERS, COLIN LOUIS

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted